Lineage Cell Therapeutics Nyseamerican Lctx has acquired privately held NeuroAirmid Therapeutics, adding an experimental Huntington s disease cell therapy to its clinical pipeline as the company reported a wider third-qu
Why Is Lineage Cell Therapeutics, Inc. (LCTX) Stock Down Today?
Updated Nov 20, 2026 6:20 PM ET · Prev Close $0.82
Session Regime & Catalyst Assessment
68% Signal ConvictionLineage Cell Therapeutics, Inc. Pulling Back 5.87% on 0.96x Relative Volume
Lineage Cell Therapeutics, Inc. (LCTX) is pulling back 5.87% (-$0.05) to $0.77 on 0.96x average session volume. Relative to benchmarks, LCTX is lagging the S&P 500 by -2.23%. 14-day RSI stands at 34.1, keeping momentum in a bearish regime.
Lineage Cell Therapeutics Nyseamerican Lctx has acquired privately held NeuroAirmid Therapeutics, adding an experimental Huntington s disease cell therapy to its clinical pipeline as the company reported a wider third-qu
Price ($0.77) trades relative to 20-day SMA ($0.97) and 50-day SMA ($0.97).
Market & Sector Relative Strength
LCTX lagging the S&P 500 by -2.23%Options Flow & Execution Desk
Recent LCTX Catalyst Headlines
Verified WireAP Lineage Cell Therapeutics, Inc. LCTX on Thursday reported third-quarter earnings of 4.
Carlsbad, Calif., November 12, 2026--Q3 2026 Earnings Release
Carlsbad, Calif., November 12, 2026--Lineage Cell Therapeutics, Inc. NYSE American and Tase Lctx , a clinical-stage biotechnology company developing allogeneic, off the shelf , cell therapies for serious medical conditio
1–3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.77 (session support) for directional breakout confirmation.
Technical Regime (LCTX)
BEARISH MA TRENDRetail & Crowd Sentiment
Very BullishA bullish StockTwits message highlights insider buying in $LCTX and $IMDX, suggesting potential positive news in the next six months.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of …
Get Instant LCTX Catalyst Alerts
Receive an email alert when LCTX triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversLCTX Session & Catalyst FAQ
Why is LCTX stock down today?
Lineage Cell Therapeutics, Inc. (LCTX) is pulling back 5.87% (-$0.05) to $0.77 on 0.96x average session volume. Relative to benchmarks, LCTX is lagging the S&P 500 by -2.23%. 14-day RSI stands at 34.1, keeping momentum in a bearish regime.
Is LCTX stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 0.96x relative volume (moderate participation). Our multi-factor model currently rates LCTX as HOLD. Review full valuation, quality, and timing signals on the LCTX Buy or Sell Decision Brief →
What is LCTX's intrinsic value and expected trading range?
At $0.77, LCTX's modeled 1-to-3 session range is $0.73 – $0.81, with a key inflection level at $0.77 (session support). Compare current price against multi-year cash flow projections in the LCTX Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for LCTX?
RSI at 34.1 reflects soft below-midline momentum. LCTX trades at $0.77 relative to its 20-day SMA ($0.97) and 50-day SMA ($0.97), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.